首页 | 本学科首页   官方微博 | 高级检索  
检索        

吉西他滨联合顺铂治疗晚期非小细胞肺癌
引用本文:张英辉.吉西他滨联合顺铂治疗晚期非小细胞肺癌[J].中国基层医药,2011,18(22):3029-3030.
作者姓名:张英辉
作者单位:海南农垦总医院肿瘤内科, 海南省海口,570326
摘    要:目的观察吉西他滨联合顺铂治疗晚期非小细胞肺癌的疗效及毒副作用。方法选择晚期非小细胞肺癌患者37例,给予吉西他滨1000-1250mg/m2,静滴,第1天及第8天;顺铂80mg/m2,静滴,第1天或分第1—3天。21d为1周期,至少完成2周期。结果全组完全缓解(CR)0例,部分缓解(PR)16例,稳定(sD)13例,总有效率(CR+PR)43.2%,肿瘤控制率(CR+PR+SD)78.4%。毒副作用主要是骨髓抑制及恶心、呕吐。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌安全有效,毒副作用可以耐受。

关 键 词:癌,非小细胞肺  吉西他滨  顺铂

The clinical observation of Gemcitabine combined with Cisplatin in the treatment of advanced non-small cell lung cancer
ZHANG Ying-hui.The clinical observation of Gemcitabine combined with Cisplatin in the treatment of advanced non-small cell lung cancer[J].Chinese Journal of Primary Medicine and Pharmacy,2011,18(22):3029-3030.
Authors:ZHANG Ying-hui
Institution:ZHANG Ying-hui. Department of Oncology,Hainan Land Reclamation General Hospital,Haikou,Hainan 570326, China
Abstract:Objective To evaluate the efficacy and toxicity of Gemcitabine combined with Cisplatin in the treatment of advanced non-small cell lung cancer.Methods Gemcitabine 1000 ~ 1250mg/m2,intravenous infusion,on d 1,8,Cisplatin 80mg/m2,intravenous infusion,on d1 or d1 ~ 3,the regimen was repeated every 21 days,completed at least 2 cycles.Results Thirty-seven patients were evaluated.None achieved CR,16 patients achieved PR,13 patients achieved SD,the overall response rate( CR + PR) was 43.2%,and the disease control rate( CR + PR + SD) was 78.4%.The most common toxicities were bone marrow suppression,nausea and vomiting.Conclusion The regimen of Gemcitabine combined with Cisplatin in the treatment of advanced non-small cell lung cancer was safe and effective,and the toxicity could be tolerated.
Keywords:Cancer  non-small cell lung  Gemcitabine  Cisplatin
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号